RESUMEN
Fexuprazan, a novel potassium-competitive acid blocker, is expected to be used for the prevention of nonsteroidal anti-inflammatory drugs (NSAIDs) induced ulcer. This study aimed to evaluate pharmacokinetic (PK) interactions between fexuprazan and NSAIDs in healthy subjects. A randomized, open-label, multicenter, six-sequence, one-way crossover study was conducted in healthy male subjects. Subjects randomly received one of the study drugs (fexuprazan 40 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID, or meloxicam 15 mg QD) for 5 or 7 days in the first period followed by the combination of fexuprazan and one of NSAIDs for the same days and the perpetrator additionally administered for 1-2 days in the second period. Serial blood samples for PK analysis were collected until 48- or 72-h post-dose at steady state. PK parameters including maximum plasma concentration at steady state (Cmax,ss) and area under plasma concentration-time curve over dosing interval at steady state (AUCτ,ss) were compared between monotherapy and combination therapy. The PKs of NSAIDs were not significantly altered by fexuprazan. For fexuprazan, differences in PK parameters (22% in Cmax, 19% in AUCτ,ss) were observed when co-administered with naproxen, but not clinically significant. The geometric mean ratio (90% confidence interval) of combination therapy to monotherapy for Cmax,ss and AUCτ,ss was 1.22 (1.02-1.46) and 1.19 (1.00-1.43), respectively. There were no significant changes in the systemic exposure of fexuprazan by celecoxib and meloxicam. Fexuprazan and NSAIDs did not show clinically meaningful PK interactions.
Asunto(s)
Antiinflamatorios no Esteroideos , Estudios Cruzados , Interacciones Farmacológicas , Humanos , Masculino , Antiinflamatorios no Esteroideos/farmacocinética , Antiinflamatorios no Esteroideos/administración & dosificación , Adulto , Adulto Joven , Voluntarios Sanos , Área Bajo la Curva , Meloxicam/farmacocinética , Meloxicam/administración & dosificación , Naproxeno/farmacocinética , Naproxeno/administración & dosificación , Celecoxib/farmacocinética , Celecoxib/administración & dosificación , Persona de Mediana EdadRESUMEN
The toxicity for the human body of non-steroidal anti-inflammatory drugs (NSAIDs) overdoses is a consequence of their low water solubility, high doses, and facile accessibility to the population. New drug delivery systems (DDS) are necessary to overcome the bioavailability and toxicity related to NSAIDs. In this context, UiO-66(Zr) metal-organic framework (MOF) shows high porosity, stability, and load capacity, thus being a promising DDS. However, the adsorption and release capability for different NSAIDs is scarcely described. In this work, the biocompatible UiO-66(Zr) MOF was used to study the adsorption and release conditions of ibuprofen, naproxen, and diclofenac using a theoretical and experimental approximation. DFT results showed that the MOF-drug interaction was due to an intermolecular hydrogen bond between protons of the groups in the defect sites, (µ3 - OH, and - OH2) and a lone pair of oxygen carboxyl functional group of the NSAIDs. Also, the experimental results suggest that the solvent where the drug is dissolved affects the adsorption process. The adsorption kinetics are similar between the drugs, but the maximum load capacity differs for each drug. The release kinetics assay showed a solvent dependence kinetics whose maximum liberation capacity is affected by the interaction between the drug and the material. Finally, the biological assays show that none of the systems studied are cytotoxic for HMVEC. Additionally, the wound healing assay suggests that the UiO-66(Zr) material has potential application on the wound healing process. However, further studies should be done.
Asunto(s)
Antiinflamatorios no Esteroideos , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Estructuras Metalorgánicas , Naproxeno , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Antiinflamatorios no Esteroideos/química , Estructuras Metalorgánicas/química , Naproxeno/administración & dosificación , Naproxeno/química , Naproxeno/farmacocinética , Ibuprofeno/administración & dosificación , Ibuprofeno/química , Ibuprofeno/farmacocinética , Humanos , Adsorción , Portadores de Fármacos/química , Diclofenaco/administración & dosificación , Diclofenaco/química , Diclofenaco/farmacocinética , Supervivencia Celular/efectos de los fármacos , Ácidos FtálicosRESUMEN
PURPOSE: Tegoprazan is a potassium-competitive acid blocker used for gastric acid suppression and may be used with NSAIDs to reduce gastrointestinal adverse effects. The aim of this study was to evaluate the pharmacokinetic interaction between tegoprazan and commonly used NSAIDS, namely, naproxen, aceclofenac, and celecoxib. METHODS: An open-label, 3-cohort, randomized, multiple-dose, 3-way crossover study was conducted in healthy male subjects. In cohort 1, tegoprazan (50-mg tablet, once daily) and naproxen (500-mg tablet, twice daily) were administered separately or concurrently for 7 days in each period. In cohort 2, tegoprazan and aceclofenac (100-mg tablet, twice daily) were administered separately or concurrently for 7 days in each period. In cohort 3, tegoprazan and celecoxib (200-mg capsule, twice daily) were administered separately or concurrently for 7 days in each period. Pharmacokinetic blood samples were collected up to 24 hours after the last dose. FINDINGS: Seventeen subjects from cohort 1, sixteen subjects from cohort 2, and thirteen subjects from cohort 3 were included in the pharmacokinetic analysis. In cohort 1, the geometric least squares mean ratios (90% CIs) for AUCτ (AUC profiles over the dosing interval) and Css,max (Cmax at steady state) were 1.01 (0.91-1.12) and 0.99 (0.83-1.17) for tegoprazan, and 1.00 (0.97-1.03) and 1.04 (0.99-1.09) for naproxen, respectively. The values in cohort 2 were 1.03 (0.93-1.13) and 0.94 (0.86-1.04) for tegoprazan, and 1.06 (1.00-1.12) and 1.31 (1.08-1.60) for aceclofenac. The values in cohort 3 were 1.01 (0.86-1.18) and 1.02 (0.87-1.19) for tegoprazan, and 1.08 (0.96-1.22) and 1.18 (0.97-1.43) for celecoxib. IMPLICATIONS: Changes in the maximum aceclofenac or celecoxib concentrations were detected after concurrent administration with tegoprazan, which were considered mainly due to the pharmacodynamic effect of tegoprazan. Because systemic drug exposure (shown as AUCτ) was unchanged after concurrent administration of any 3 NSAIDs with tegoprazan, the increase in aceclofenac or celecoxib Css,max when administered with tegoprazan would not be clinically significant in practice. CLINICALTRIALS: gov Identifier: NCT04639804.
Asunto(s)
Antiinflamatorios no Esteroideos , Naproxeno , Administración Oral , Área Bajo la Curva , Derivados del Benceno , Celecoxib/efectos adversos , Estudios Cruzados , Diclofenaco/análogos & derivados , Humanos , Imidazoles , Masculino , Naproxeno/efectos adversos , Naproxeno/farmacocinética , República de Corea , ComprimidosRESUMEN
A drug delivery system based on mesoporous particles MCM-41 was post-synthetically modified by photo-sensitive ligand, methyl-(2E)-3-(4-(triethoxysilyl)-propoxyphenyl)-2-propenoate (CA) and the pores of MCM-41 particles were loaded with Naproxen sodium salt (NAP). The CA was used as a photoactive molecule that can undergo a reversible photo-dimerization by [2π + 2π] cycloaddition when irradiated with UV light of specific wavelengths. Thus, it has a function of gate-keeper that is responsible for opening/closing the pores and minimizing premature release of NAP. The physicochemical properties of the prepared system were studied by infrared spectroscopy (IR), nitrogen adsorption measurements, thermogravimetric analysis (TGA), scanning transmission electron microscopy (STEM) and energy dispersive X-ray spectroscopy (EDX). The mechanism of the opening/closing pores was confirmed by UV measurements. In vitro and in vivo drug release experiments and the concentration of released NAP was determined by UV spectroscopy and high-performance liquid chromatography (HPLC). In vivo drug release in the blood circulatory system of rats has demonstrated the effective photo-cleavage reaction of CA molecules after UV-light stimulation. The localization and morphological changes of the particles were studied in the blood and liver of rats at different time intervals. The particles in the blood have been shown to retain their original rod-like shape, and the particles in the liver have been hydrolysed, which has resulted in spherical shape with a reduced size.
Asunto(s)
Portadores de Fármacos/química , Naproxeno , Dióxido de Silicio/química , Animales , Liberación de Fármacos , Masculino , Naproxeno/administración & dosificación , Naproxeno/farmacocinética , Ratas , Ratas Wistar , SolubilidadRESUMEN
BACKGROUND AND OBJECTIVE: Bioequivalence tests are fundamental step in assessing the equivalence in bioavailability between a test and reference product. In practice, two separate linear mixed models (LMMs) with random subject effects, which have an area under the concentration-time curve (AUC) and the peak concentration (Cmax) as the responses, have become the gold standard for evaluating bioequivalence. Recently, Lee et al developed a multivariate hierarchical generalized linear model (HGLM) for several responses that modeled correlations among multivariate responses via correlated random effects. The objective of this study was to apply this multivariate analysis to the bioequivalence test in practice and to compare the performance of multivariate HGLM and separate LMMs. METHODS: Three pharmacokinetic datasets, fixed-dose combination (naproxen and esomeprazole), tramadol and fimasartan data were analyzed. We compared the 90% confidence interval (CI) for the geometric mean ratio (GMR) of a test product to a reference product using the multivariate HGLM and two conventional separate LMMs. RESULTS: We found that the 90% CIs for the GMRs of both AUC and Cmax from the multivariate HGLM were narrower than those from the separate LMMs: (0.843, 1.152) vs (0.825, 1.177) for Cmax of esomeprazole in fixed-dose combination data; (0.805, 0.931) vs (0.797, 0.941) for Cmax in tramadol data; (0.801, 1.501) vs (0.762, 1.578) for Cmax and (1.163, 1.332) vs (1.009, 1.341) for AUC in fimasartan data, consistent with the random subject effects from two separate LMMs being highly correlated in the three datasets (correlation coefficient r = 0.883; r = 0.966; r = 0.832). CONCLUSION: This multivariate HGLM had good performance in the bioequivalence test with multiple endpoints. This method would provide a more reasonable option to reduce the 90% CI by adding correlation parameters and thus an advantage especially in evaluating the bioequivalence of highly variable drugs with broad 90% CIs.
Asunto(s)
Compuestos de Bifenilo/farmacocinética , Esomeprazol/farmacocinética , Modelos Estadísticos , Pirimidinas/farmacocinética , Tetrazoles/farmacocinética , Tramadol/farmacocinética , Área Bajo la Curva , Disponibilidad Biológica , Compuestos de Bifenilo/administración & dosificación , Conjuntos de Datos como Asunto , Combinación de Medicamentos , Esomeprazol/administración & dosificación , Humanos , Modelos Lineales , Masculino , Análisis Multivariante , Naproxeno/administración & dosificación , Naproxeno/farmacocinética , Pirimidinas/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Tetrazoles/administración & dosificación , Equivalencia Terapéutica , Tramadol/administración & dosificaciónRESUMEN
In this study, an attempt was made to produce Liqui-Tablets for the first time. This was carried out through the compaction of naproxen Liqui-Pellets. The incentive to convert the novel Liqui-Pellet into Liqui-Tablet was due to the array of inherent advantages of the popular and preferred tablet dosage form. The study showed that naproxen Liqui-Tablet could be successfully produced and the rapid drug release rate (100% drug release ~ 20 min) could be achieved under pH 1.2, where naproxen is insoluble. It was observed that the different pH of the dissolution medium affected the trend of drug release from formulations with varying amounts of liquid vehicle. The order of the fastest drug-releasing formulations was different depending on the pH used. The presence of Neusilin US2 showed considerable enhancement in the drug release rate as well as improving Liqui-Tablet robustness and hardness. Furthermore, images from X-ray micro-tomography displayed a uniform distribution of components in the Liqui-Tablet. The accelerated stability studies showed acceptable stability in terms of dissolution profile.
Asunto(s)
Composición de Medicamentos/métodos , Naproxeno/administración & dosificación , Naproxeno/síntesis química , Tecnología Farmacéutica/métodos , Administración Oral , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/farmacocinética , Formas de Dosificación , Liberación de Fármacos , Excipientes/administración & dosificación , Excipientes/síntesis química , Excipientes/farmacocinética , Naproxeno/farmacocinética , ComprimidosRESUMEN
In this study, the aerogel technology was used to prepare pulmonary drug carriers consisting of alginate and alginate-hyaluronic acid by an emulsion gelation technique and supercritical CO2 drying. During the preparation process, the emulsification rate and inner phase viscosity were varied to control the diameter of aerogel microspheres. Results showed that the aerogel microspheres were highly porous (porosity > 98%) with low densities in the range between 0.0087 and 0.0634 g/cm3 as well as high surface areas between 354 and 759 m2/g. The obtained microspheres showed aerodynamic diameter below 5 µm making them suitable for pulmonary drug delivery. An in vitro drug release study with the model drug sodium naproxen was conducted and a non-Fickian drug release mechanism was observed, with no significant difference between the release profiles of alginate and alginate-hyaluronic acid microspheres. During the emulsion gelation step, the feasibility of using the capillary number to estimate the largest stable droplet size in the emulsions was also studied and it was found that using this number, the droplet size in the emulsions may well be predicted.
Asunto(s)
Alginatos/química , Sistemas de Liberación de Medicamentos , Ácido Hialurónico/química , Naproxeno/administración & dosificación , Química Farmacéutica , Portadores de Fármacos/química , Liberación de Fármacos , Emulsiones , Geles , Pulmón/metabolismo , Microesferas , Naproxeno/farmacocinética , Tamaño de la Partícula , Porosidad , Tecnología Farmacéutica , Distribución Tisular , ViscosidadRESUMEN
Naproxen is a widely used non-steroidal anti-inflammatory drug for the control of postoperative inflammatory signs and symptoms in dentistry. Its association with esomeprazole has been widely studied and has yielded good results for the control of acute pain, even with the delayed absorption of naproxen owing to the presence of esomeprazole. To further understand the absorption, distribution, and metabolism of this drug alone and in combination with esomeprazole, we will analyze the pharmacokinetic parameters of naproxen and its major metabolite, 6-O-desmethylnaproxen, in saliva samples. A rapid, sensitive, and selective liquid chromatography-tandem mass spectrometric method for the simultaneous determination of naproxen and 6-O-desmethylnaproxen in saliva will be developed and validated. Sequential saliva samples from six patients will be analyzed before and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6 8, 11, 24, 48, 72, and 96 h after the ingestion of one naproxen tablet (500 mg) and esomeprazole-associated naproxen tablets (500 + 20 mg), at two different times. After liquid-liquid extraction with ethyl acetate and HCl, the samples will be analyzed using an 8040 Triple Quadrupole Mass Spectrometer (Shimadzu, Kyoto, Japan). Separation of naproxen and its major metabolic products will be performed using a Shim-Pack XR-ODS 75Lx2.0 column and C18 pre-column (Shimadzu, Kyoto, Japan) at 40°C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v) with an injection flow of 0.3 mL/min. The total analytical run time will be 5 min. The detection and quantification of naproxen and its metabolite will be validated, which elucidate the pharmacokinetics of this drug, thereby contributing to its proper prescription for the medical and dental interventions that cause acute pain.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Monitoreo de Drogas/métodos , Esomeprazol/farmacocinética , Naproxeno/análogos & derivados , Saliva/química , Administración Oral , Adolescente , Adulto , Antiinflamatorios no Esteroideos/aislamiento & purificación , Cromatografía Líquida de Alta Presión/métodos , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Esomeprazol/administración & dosificación , Esomeprazol/aislamiento & purificación , Femenino , Absorción Gastrointestinal , Humanos , Masculino , Metanol/química , Persona de Mediana Edad , Naproxeno/administración & dosificación , Naproxeno/aislamiento & purificación , Naproxeno/farmacocinética , Dolor Asociado a Procedimientos Médicos/tratamiento farmacológico , Reproducibilidad de los Resultados , Comprimidos , Espectrometría de Masas en Tándem/métodos , Adulto JovenRESUMEN
Prediction of human pharmacokinetics is important in the preclinical stage. Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions. Although several physiological and empirical methods including single-species allometry for prediction of values for human clearance of compounds using humanized-liver mice have been reported, further improvement of prediction accuracies would be still expected. To optimize these approaches, we proposed methods for unbound intrinsic clearance in virtually 100% humanized-liver mouse by incorporating unbound plasma fractions of compounds in differently humanized-liver mice. Comparisons of prediction accuracies of values for human clearance of 15 model compounds were performed among our current physiological and previously reported models and single-species allometry using humanized-liver mice. Incorporation of the actual unbound plasma fractions of compounds and correction of residual mice hepatocyte in humanized-liver mice showed comparable prediction accuracy to that by single-species allometry. After exclusion of 3 compounds with large species differences in values of clearance and unbound plasma fractions between mice and humans out of 15 compounds, prediction accuracies were improved in the methods investigated. The previously and present reported physiological methods could show the good prediction accuracy of values for clearance of drugs from plasma.
Asunto(s)
Hígado/metabolismo , Preparaciones Farmacéuticas/sangre , Preparaciones Farmacéuticas/metabolismo , Acetamidas/sangre , Acetamidas/farmacocinética , Albuterol/sangre , Albuterol/farmacocinética , Animales , Carbamatos/sangre , Carbamatos/farmacocinética , Cromatografía Liquida , Diazepam/sangre , Diazepam/farmacocinética , Diclofenaco/sangre , Diclofenaco/farmacocinética , Digitoxina/sangre , Digitoxina/farmacocinética , Humanos , Itraconazol/sangre , Itraconazol/farmacocinética , Cetoprofeno/sangre , Cetoprofeno/farmacocinética , Hígado/química , Tasa de Depuración Metabólica , Ratones , Ratones Transgénicos , Naproxeno/sangre , Naproxeno/farmacocinética , Fenitoína/sangre , Fenitoína/farmacocinética , Piperidinas/sangre , Piperidinas/farmacocinética , Pravastatina/sangre , Pravastatina/farmacocinética , Pirimidinas/sangre , Pirimidinas/farmacocinética , Quinidina/sangre , Quinidina/farmacocinética , Espectrometría de Masas en Tándem , Telmisartán/sangre , Telmisartán/farmacocinética , Terfenadina/análogos & derivados , Terfenadina/sangre , Terfenadina/farmacocinética , Verapamilo/sangre , Verapamilo/farmacocinéticaRESUMEN
OBJECTIVE: Naproxen sodium (NAPSO) is commonly used in a variety of pain conditions. There are several strengths of NAPSO available over the counter (OTC). Most published data are based on single or multiple doses using 220 mg, hence there is a need to assess the analgesic efficacy of other strengths of NAPSO used in the OTC setting. MATERIALS AND METHODS: We reviewed published and unpublished studies of naproxen (NAP) and NAPSO to establish the pharmacokinetic relationship between dosage, plasma concentration, and efficacy, and to compare the analgesic efficacy of NAPSO 220, 440, and 550 mg or NAP 500 mg versus placebo and active comparators. RESULTS: Increasing OTC doses of NAP are associated with linear pharmacokinetics, i.e., plasma levels of NAP increase proportionately with dosage. Accordingly, the therapeutic efficacy of higher doses of NAP or NAPSO is greater than lower doses. All OTC doses of NAP and NAPSO are significantly more effective than placebo. Higher strengths are as effective or more effective than lower strengths, and at least comparable to other active treatments. CONCLUSION: The pharmacokinetic linearity associated with NAP means that data on efficacy for the lower OTC doses of NAPSO can be extrapolated to the higher OTC doses. Thus, it is given that NAPSO 275 and 550 mg will be at least as effective as or superior to the lower doses of 220 and 440 mg.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Naproxeno/farmacocinética , Humanos , Medicamentos sin Prescripción/farmacocinéticaRESUMEN
Purpose: The aim of this study was to design naproxen sodium (NS)-containing, biomimetic, porous poly(lactide-co-glycolide) (PLGA) scaffolds for regeneration of damaged corneal epithelium. Methods: NS-incorporated PLGA scaffolds were prepared using the emulsion freeze-drying method and then coated with collagen or poly-l-lysine. Porosity measurements of the scaffolds were performed by the gas adsorption/desorption method and the scaffolds demonstrated highly porous, open-cellular pore structures with pore sizes from 150 to 200 µm. Results: The drug loading efficiency of scaffolds was found to be higher than 84%, and about 90%-98% of NS was released at the end of 7 days with a fast drug release rate at the initial period of time and then in a slow and sustained manner. The corneal epithelial cells were isolated from New Zealand white rabbits. The obtained cells were seeded onto scaffolds and continued to increase during the time period of the study, indicating that the scaffolds might promote corneal epithelial cell proliferation without causing toxic effects for at least 10 days. Conclusions: The NS-loaded PLGA scaffolds exhibited a combination of controlled drug release and biomimetic properties that might be attractive for use in treatment of corneal damage both for controlled release and biomedical applications.
Asunto(s)
Antiinflamatorios/farmacocinética , Lesiones de la Cornea/tratamiento farmacológico , Epitelio Corneal/efectos de los fármacos , Naproxeno/farmacocinética , Ingeniería de Tejidos/métodos , Andamios del Tejido/química , Animales , Antiinflamatorios/administración & dosificación , Biomimética , Proliferación Celular/efectos de los fármacos , Colágeno/química , Colágeno/metabolismo , Composición de Medicamentos/métodos , Liberación de Fármacos , Epitelio Corneal/patología , Naproxeno/administración & dosificación , Polietilenglicoles/química , Polietilenglicoles/metabolismo , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/farmacocinética , Polilisina/análogos & derivados , Polilisina/química , Polilisina/metabolismo , Porosidad/efectos de los fármacos , Conejos , Regeneración/efectos de los fármacos , Regeneración/fisiologíaRESUMEN
BACKGROUND: Physiologically-based population pharmacokinetic modeling (popPBPK) coupled with in vitro biopharmaceutics tools such as biorelevant dissolution testing can serve as a powerful tool to establish virtual bioequivalence and set clinically relevant specifications. One of several applications of popPBPK modeling is in the emerging field of virtual bioequivalence (VBE), where it can be used to streamline drug development by implementing model-informed formulation design and to inform regulatory decision-making e.g., with respect to evaluating the possibility of extending BCS-based biowaivers beyond BCS Class I and III compounds in certain cases. METHODS: In this study, Naproxen, a BCS class II weak acid was chosen as the model compound. In vitro biorelevant solubility and dissolution experiments were performed and the resulting data were used as an input to the PBPK model, following a stepwise workflow for the confirmation of the biopharmaceutical parameters. The naproxen PBPK model was developed by implementing a middle-out approach and verified against clinical data obtained from the literature. Once confidence in the performance of the model was achieved, several in vivo dissolution scenarios, based on model-based analysis of the in vitro data, were used to simulate clinical trials in healthy adults. Inter-occasion variability (IOV) was also added to critical physiological parameters and mechanistically propagated through the simulations. The various trials were simulated on a "worst/best case" dissolution scenario and average bioequivalence was assessed according to Cmax, AUC and Tmax. RESULTS: VBE results demonstrated that naproxen products with in vitro dissolution reaching 85% dissolved within 90 min would lie comfortably within the bioequivalence limits for Cmax and AUC. Based on the establishment of VBE, a dissolution "safe space" was designed and a clinically relevant specification for naproxen products was proposed. The interplay between formulation-related and drug-specific PK parameters (e.g., t1/2) to predict the in vivo performance was also investigated. CONCLUSION: Over a wide range of values, the in vitro dissolution rate is not critical for the clinical performance of naproxen products and therefore naproxen could be eligible for BCS-based biowaivers based on in vitro dissolution under intestinal conditions. This approach may also be applicable to other poorly soluble acidic compounds with long half-lives, providing an opportunity to streamline drug development and regulatory decision-making without putting the patient at a risk.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Liberación de Fármacos , Modelos Biológicos , Naproxeno/química , Naproxeno/farmacocinética , Administración Intravenosa , Administración Oral , Adolescente , Adulto , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Solubilidad , Equivalencia Terapéutica , Adulto JovenRESUMEN
Liqui-pellet is a new dosage form stemming from pelletisation technology and concept from liquisolid technology. In spite of liqui-pellet overcoming a major hurdle in liquisolid technology through achieving excellent flow property with high liquid load factor, the formulation requires to be optimised in order to improve drug release rate. Liqui-pellets of naproxen containing Tween 80, Primojel, Avicel and Aerosil were extruded and spheronised. Flowability test confirmed that all liqui-pellet formulations have excellent-good flow property (Carr's index between 3.9-11.17%), including liqui-pellets with a high liquid load factor of 1.52, where 38% of the total mass is co-solvent. This shows a relatively high liquid load factor can be achieved in liqui-pellet without compromising the flowability, which is one of the key novelty of this work. It was found that the improved drug release rate was due to the remarkably improved disintegration of the supposedly non-disintegrating microcrystalline-based pellet; the optimised liqui-pellet seems to explode into fragments in the dissolution medium. At pH 1.2, the optimised formulation had ~ 10% more drug release than non-optimised formulation after 2 h, and at pH 7.4, the drug release of the optimised pellet was nearing 100% at ~ 15 min, whereas the none-optimised pellet only achieved ~ 79% drug release after 2 h. DSC and XRPD indicated an increase in the dissolution rate could be due to molecularly dispersion of naproxen in the pellets. Overall results showed that liqui-pellet exhibited an enhanced drug release and the capacity for high liquid load factor whilst maintaining excellent flowability, rendering it a potentially commercially feasible drug delivery system.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Formas de Dosificación , Naproxeno/administración & dosificación , Administración Oral , Antiinflamatorios no Esteroideos/farmacocinética , Naproxeno/farmacocinética , Solubilidad , Tensión Superficial , Tecnología FarmacéuticaRESUMEN
The spectroscopic (FT-IR, FT-Raman, NMR), electronic (UV--Vis.), structural and thermodynamical properties of an anti-inflammatory analgesic called Naproxen Sodium, (s)-6-methoxy-α-methyl-2-naphthaleneacetic acid sodium salt are submitted by using both experimental techniques and theoretical methods as quantum chemical calculations in this work. The equilibrium geometry and vibrational spectra are calculated by using DFT (B3LYP) with 6-311++G (d,p) basis set using GAUSSIAN 09. The vibrational wavenumbers are also corrected with scale factor to take better results for the calculated data. The HOMO-LUMO calculations are carried out on the title compound. The theoretical and experimental NMR peaks were found to be in good agreement. In addition, the detailed study on the Non-Bonding Orbitals, the excitation energies, AIM charges, condensed fukui calculations, thermodynamical properties, Localized Orbital Locator (LOL) and Electron Localization Function (ELF) are also performed. Furthermore, the study is extended to calculate the first order hyperpolarizability and to predict its NLO properties. The docking studies details helped on predicting the binding with different proteins.
Asunto(s)
Biología Computacional/métodos , Conformación Molecular , Naproxeno/química , Teoría Cuántica , Análisis Espectral , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Naproxeno/farmacocinética , Espectrofotometría Ultravioleta , Espectroscopía Infrarroja por Transformada de Fourier , Análisis Espectral/métodos , Espectrometría Raman , Termodinámica , VibraciónRESUMEN
The present study was designed with an aim to develop and optimize naproxen proniosomes (NAPRNs) using Box-Behnken Design (BBD). The formulation was optimized using three independent variables [maltodextrin (X1), surfactant concentration (X2) and drug concentration (X3)] at three different levels (low, medium and high). The prepared fifteen formulations were evaluated for drug entrapment efficiency, vesicle size and transdermal flux to select the optimized naproxen niosomes (NAPRNopt). The developed NAPRNs formulations showed the nano-size vesicle (218-417 nm) and high encapsulation efficiency (60.48-92.48%) with high flux value (23.17-27.37 µg/cm2/h). The formulation NAPRNopt has shown the vesicle size of 376.12 ± 4.12 nm with entrapment efficiency 86.43 ± 3.63% and transdermal flux of 27.56 ± 1.43 µg/cm2/h. The SEM study revealed the formulation NAPRNopt showed irregular surface morphology of niosomes. The formulation NAPRNopt gel showed biphasic release behaviour as an initial fast release and later slower release with the Higuchi release mechanism. The anti-inflammatory study results showed a better effect than the standard NAP gel in the rat model.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Liposomas/metabolismo , Naproxeno/metabolismo , Absorción Cutánea , Piel/metabolismo , Administración Cutánea , Algoritmos , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacocinética , Carragenina , Liberación de Fármacos , Edema/inducido químicamente , Edema/prevención & control , Cinética , Liposomas/farmacocinética , Liposomas/ultraestructura , Microscopía Electrónica de Rastreo , Naproxeno/farmacocinética , Tamaño de la Partícula , RatasRESUMEN
This work aimed to design and synthesize a safe nonsteroidal anti-inflammatory drug NSAIDs agent based on Naproxen scaffold. The structure of compounds 6-21 established on the basis of different spectral data. Anti-inflammatory and analgesic profile were examined for synthesizing compounds. The compounds 6 and 17 have shown a higher anti-inflammatory potency than Naproxen. The compounds 16, 19 and 21 have exhibited the highest analgesic potency compared to other tested compounds. The synthesized compounds have shown negligible ulcerogenic effect and may be considered as safer drugs than naproxen for treating inï¬ammatory conditions. The molecular docking against COX-2 was performed, it verified that compound 6, 17 show stronger interactions with COX-2. This may result in a better inhibitory effect on COX-2. The best generated QSAR model shows correlation between BCUT_SMR_3 and vsurf_Wp6 with biological activity. ADMET in silico showed that these compounds are a good oral bioavailability without observed carcinogenesis affect.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Diseño de Fármacos , Simulación del Acoplamiento Molecular , Naproxeno/síntesis química , Naproxeno/farmacología , Relación Estructura-Actividad Cuantitativa , Analgésicos/química , Animales , Antiinflamatorios no Esteroideos/química , Ligandos , Naproxeno/química , Naproxeno/farmacocinética , RatasRESUMEN
The blood brain barrier is a major obstacle to the entry of the majority of CNS-active agents. In the present research, the potential of magnetic polymeric micelles (MPMs) for brain-targeting of naproxen was evaluated. The MPMs were made of methoxy poly(ethyleneglycol)-poly (caprolactone) copolymer and super paramagnetic iron oxide nanoparticles (SPIONs). To investigate the impact of particle size on the in vivo biofate of nanoparticles, MPMs with two different sizes were prepared. The prepared magnetic polymeric micelles had diameters of 137⯱â¯3.5â¯nm (MPM137) and 242⯱â¯6.2â¯nm (MPM242) and their surface charges were about -6.5 andâ¯-â¯4.5â¯mV, respectively. Pharmacokinetic and biodistribution of nanoparticles were characterized in rats using an external magnet of 0.4 Tesla field strength located on the skull of anesthetized animals. Significant differences in volumes of central as well as peripheral compartments were observed between both MPM formulations and free naproxen solution. After 8â¯h of administration, the brain concentration of naproxen was shown to be higher in the case of MPM137 in comparison with MPM242 and free drug. The findings revealed that the polymeric magnetic micelles with diameters smaller than 150â¯nm could be initially considered as a promising carrier to improve therapeutic agent accumulation in the brain for the treatment of CNS diseases.
Asunto(s)
Encéfalo/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Magnetismo , Micelas , Naproxeno/farmacología , Naproxeno/farmacocinética , Polímeros/química , Animales , Liberación de Fármacos , Masculino , Nanopartículas/química , Nanopartículas/ultraestructura , Naproxeno/administración & dosificación , Naproxeno/sangre , Tamaño de la Partícula , Poliésteres/síntesis química , Poliésteres/química , Polietilenglicoles/síntesis química , Polietilenglicoles/química , Espectroscopía de Protones por Resonancia Magnética , Ratas Sprague-Dawley , Espectroscopía Infrarroja por Transformada de Fourier , Electricidad Estática , Factores de Tiempo , Distribución Tisular/efectos de los fármacosRESUMEN
BACKGROUND/AIMS: The mechanisms by which permeation enhancers increase human skin permeation of caffeine and naproxen were assessed in vitro. METHODS: Active compound solubility in the vehicles and in the stratum corneum (SC), active compound flux across epidermal membranes and uptake of active and vehicle components into the SC were measured. The effect of vehicle pH on the permeation of caffeine and naproxen was also determined. RESULTS: Oleic acid and eucalyptol significantly enhanced the skin penetration of caffeine and naproxen, compared to aqueous controls. Naproxen permeation was increased from vehicles with pH presenting more ionized naproxen. Caffeine maximum flux enhancement was associated with an increase in caffeine SC solubility and skin diffusivity, whereas for naproxen a penetration enhancer/vehicle-induced increase in solubility in the SC correlated with an increase in maximum flux. SC solubility was related to experimentally determined active uptake, which was in turn predicted by vehicle uptake and active compound solubility in the vehicle. CONCLUSION: A permeation enhancer-induced alteration in diffusivity, rather than effects on SC solubility, was the main driving force behind increases in permeation flux of the hydrophilic molecule caffeine. For the more the lipophilic molecule naproxen, increased SC solubility drove the increases in permeation flux.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Cafeína/farmacocinética , Epidermis/efectos de los fármacos , Naproxeno/farmacocinética , Vehículos Farmacéuticos/farmacología , Absorción Cutánea/efectos de los fármacos , Epidermis/metabolismo , Etanol/farmacología , Eucaliptol/farmacología , Femenino , Humanos , Concentración de Iones de Hidrógeno , Ácido Oléico/farmacología , Permeabilidad , Polietilenglicoles/farmacología , Dodecil Sulfato de Sodio/farmacologíaRESUMEN
Naproxen (Npx) was utilized as an anionic drug and loaded in the deproteinized natural rubber (DPNR) films prepared by the UV irradiation. The in-vitro drug release-permeation from the DPNR films and through the pig skin was investigated under the effects of the plasticizer type and amount, silicone oil (Si) and dibutyl phthalate (DBP), applied electric potential, and used conductive polyazulene as the drug encapsulation host. The drug release-permeation consisted of 2 successive periods: the pore formation period and release-permeation period. In the first period, the scaling exponent n1 values were between 0.5 and 1 indicating the decreasing drug rate with time. In the second stage, the scaling exponent n2 values were higher than 1 indicating the increasing drug rate with time. The Npx release-permeation amount increased with increasing amount of hydrophilic plasticizers. The efficiency of plasticizers on the Npx release-permeation amount was ranked as follows: DBPâ¯>â¯Si. The Npx release-permeation amount was drastically enhanced from the applied electrical potential due to the electro-repulsive force between the negatively charged drug and the negatively charged electrode, and the presence of the Npx-doped conductive polyazulene. Other characteristics were also investigated in details namely the matrix morphology, and the pore formation during the two periods.
Asunto(s)
Azulenos/química , Naproxeno/química , Plastificantes/química , Polímeros/química , Goma/química , Parche Transdérmico , Animales , Dibutil Ftalato/química , Liberación de Fármacos , Electricidad , Naproxeno/farmacocinética , Permeabilidad , Aceites de Silicona/química , Piel/metabolismo , PorcinosRESUMEN
Adsorption behavior of pure enantiomers and racemic mixtures of nonsteroidal anti-inflammatory drugs (ibuprofen and naproxen) on human serum albumin (HSA) was evaluated. The HSA was immobilized by Sol-Gel technique and this biomaterial was used in a chromatographic system where frontal analysis experiments were performed at pH 7.4 and temperatures of 25°C and 37°C. The association constants for enantiomers of the drugs were determined by linear adjustment for data corrected just for dead volume. In uncorrected data for non-specific retention, an inverse ratio between the number of sites and the value of the association constant was found. The participation of non-specific retention was estimated by non-linear regression and the values of association constants (Kass), which were determined considering this information, are comparable to some values reported by other methods at 37°C: 1.4 x105 and 5.7 x104 for Ibuprofen (IBU) R and S, respectively, and 2.3 x105 and 1.8x105 for naproxen (NX) R and S, respectively.